When taken orally, glutathione is broken down in the stomach before reaching the cells that need it
Clinical trial data from the SURMOUNT and SURPASS programs showed tirzepatide patients losing an average of 20 to 25 percent of body weight at the highest doses, compared to roughly 15 to 17 percent for semaglutide in similar trials
Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation
The study was led by first author Isabella de Vere Hunt, MD, with co-authors Mariana Ramirez-Posada, Christopher Sam Babu, Cati Brown-Johnson, PhD, Eleni Linos, MD, MPH, DrPH, and Fatima Rodriguez, MD, MPH